Soliqua 33 µg/mL and 100 units/mL, 50 µg/mL and 100 units/mL Solution for injection
PDF Leaflet Revision Date: 19 September 2024
Clinical Summary
Quick overview from the medicine insert
Indication
For treatment of adults with type 2 diabetes mellitus to improve glycaemic control.
Dosage (summary)
Administer subcutaneously once daily, titrate based on clinical response; max 60 units.
Special Populations
- Elderly patients
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Oral antidiabetics
- Corticosteroids
- Sulphonylureas
Contraindications
- Hypersensitivity to components
- Hypoglycaemia
- Acute pancreatitis
- Severe renal impairment
- Pregnancy
- Lactation
Common side effects
- Hypoglycaemia
- Nausea
- Diarrhoea
- Vomiting
Counselling Points
- Rotate injection sites
- Monitor blood glucose regularly
- Recognize symptoms of hypoglycaemia
Serious warnings
- Risk of pancreatitis
- Hypoglycaemia risk
- Injection site reactions
Important Disclaimer
The Soliqua 33 µg/mL and 100 units/mL, 50 µg/mL and 100 units/mL Solution for injection professional information leaflet below is the property of Sanofi-Aventis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
